tag:blogger.com,1999:blog-2986124651030959736.post7939345718018584760..comments2024-03-26T21:50:50.895-05:00Comments on Stocks, Bonds & Politics: Observations and Sample of Recent Trades (GJS & GJT: Synthetic Floaters); KGFHY TENNINDEPENDENThttp://www.blogger.com/profile/17444227958539559639noreply@blogger.comBlogger8125tag:blogger.com,1999:blog-2986124651030959736.post-32258788753986227722017-07-12T11:59:29.827-05:002017-07-12T11:59:29.827-05:00Thank you for continuing to provide a spotlight o...Thank you for continuing to provide a spotlight on the decadent underbelly of politics, the financial markets in general, and the biotech/pharmaceutical sector in particular.<br /><br /><br />InAvalonhttps://www.blogger.com/profile/11099271792479219061noreply@blogger.comtag:blogger.com,1999:blog-2986124651030959736.post-81200151449126386482017-07-12T11:13:10.270-05:002017-07-12T11:13:10.270-05:00OMER and "Art Doyle": Doyle is continuin...OMER and "Art Doyle": Doyle is continuing his assaults on OMER via Twitter after Scribd took down his short reports. <br /><br /> https://twitter.com/artdoyle2017?lang=en<br /><br />He, she or it claims that OMER has yet to dose a single patient in the OMS721 Phase 3 trial for Atypical Hemolytic Uremic Syndrome.<br /><br />If that allegation is true, and I have not been able to find any evidence yet that it is false, then I have a common sense type of question. If this compound is such a game changer for those with this malady, why aren't those people knocking down the door to enroll? <br /><br />Normally, a small biotech company will issue a press release when the first patient is dosed in a phase 3 trial. <br /><br />A couple of recently SA articles disparage "Doyle's" research, and most of the comments agree since SA readers only like articles that provide confirmation bias to what they already own. <br /><br />A couple of comments express some suspicion about why so few patients were dosed in phase 2 if OMS721 was such a miracle drug. <br /><br />See comment of <br />Wlodzimierz M Wisniewski, MD<br /><br />"They had phase 2 study in only 4 patients in IgAN populations and going right away into phase 3. Phase 2 should serve a purpose of establishing some efficacy level, durability and dosing so successful phase 3 can be designed. With 4 patients only in phase 2 one should worry about situations where phase 3 protocol will have to be changed on the way and problems with FDA down the road. With 120 K patients affected in USA and no good treatment for it, it is not like patients are not available for trial."<br /><br /> https://seekingalpha.com/article/4086070-omeros-pipeline-starting-get-recognition-deserves<br /><br />That seems like a reasonable level of skepticism given the facts. <br /><br /><br />I previously discussed selling my other 30 share lot at $21.61 that was bought earlier this year at $9.35: <br /><br />Item # 2.E.<br />https://tennesseeindependent.blogspot.com/2017/07/observations-and-sample-of-recent.html<br /><br /><br />In the press release dated 6/13/2017 announcing the FDA decision to grant OMS721 breakthrough status for IgA Nephropathy, OMER stated that the phase 3 trials would begin this year. <br /><br />http://www.businesswire.com/news/home/20170613005978/en/TENNINDEPENDENThttps://www.blogger.com/profile/17444227958539559639noreply@blogger.comtag:blogger.com,1999:blog-2986124651030959736.post-52829786245350901362017-07-11T15:47:55.246-05:002017-07-11T15:47:55.246-05:00Fidelity has not accepted online orders for synthe...Fidelity has not accepted online orders for synthetic floaters since 2010. <br /><br />https://tennesseeindependent.blogspot.com/2010/12/fidelity-extends-denial-of-trading.html<br /><br />That is not unusual for Fidelity, particularly in the exchange traded bond and floating rate equity preferred stock categories. A large number of securities are off limits to their customers. <br /><br />I can buy the synthetic floaters in my IB, Vanguard and Schwab accounts. The Roth IRA purchase of GJS was in my Vanguard Roth IRA account. The other GJS purchase was in my Interactive Brokers taxable trading account. The GJT purchase was made in my Schwab taxable account using a commission free trade. <br /><br />One reader mentioned to me that he had fired a broker and moved his assets to another broker due to one problem. If I fired a broker for one problem, I would not have any brokers left to fire. <br /><br />I run into different types of problems at every broker. Fidelity is good at foreign tax dividend withholding issues but but is bad on buying an array of equity preferred and exchange traded bonds. It does no good whatsoever to raise those prohibitions with them as I started to do in 2010 without any relief. <br /><br />Try to buy AMJ (an ETN that tracks energy infrastructure MLPs), MSPRA or AEB from Fidelity for example. All are prohibited by that firm. The prohibition also extends to all "principal protected" exchange traded bonds. TENNINDEPENDENThttps://www.blogger.com/profile/17444227958539559639noreply@blogger.comtag:blogger.com,1999:blog-2986124651030959736.post-76383463154867512802017-07-11T14:53:18.832-05:002017-07-11T14:53:18.832-05:00Fidelity will not accept orders for GJS nor GJ, wh...Fidelity will not accept orders for GJS nor GJ, who did you buy it from?Anonymousnoreply@blogger.comtag:blogger.com,1999:blog-2986124651030959736.post-86894966971124948482017-07-10T15:48:34.058-05:002017-07-10T15:48:34.058-05:00I have published a new post which updates my Excha...I have published a new post which updates my Exchange Traded Bonds and Preferred Stocks Basket, which was last updated in August 2016: <br /><br /> https://tennesseeindependent.blogspot.com/2017/07/current-exchange-traded-bonds-and.htmlTENNINDEPENDENThttps://www.blogger.com/profile/17444227958539559639noreply@blogger.comtag:blogger.com,1999:blog-2986124651030959736.post-9233848359549073942017-07-10T13:00:32.299-05:002017-07-10T13:00:32.299-05:00CCP & SBRA: I mentioned buying 40 shares of CC...CCP & SBRA: I mentioned buying 40 shares of CCP recently to bring my position over 100 shares. <br /><br />Item 5.B. <br />https://tennesseeindependent.blogspot.com/2017/06/observations-and-sample-of-recent_17.html<br /><br />As mentioned in that post, CCP has agreed to be acquired by Sabra Healthcare at 1.123 SBRA shares for each CCP share. <br /><br />SBRA's share price has been sinking due to problems with one of its tenants NMS Healthcare. <br /><br />http://www.marylandattorneygeneral.gov/News%20Documents/State_v_NMS_Complaint.pdf<br /><br />Closure of Facility at Hagerstown<br />http://www.heraldmailmedia.com/news/local/medicaid-payments-stopped-at-nms-healthcare-of-hagerstown/article_0acfc9d1-7fd6-5b4c-bfc4-4c7481c86fdc.html<br /><br />SBRA owns that facility: <br /><br />Page F-51 previous link<br /><br />I do not have access to the reports recently issued by Mizuho Securities, which downgraded SBRA to underperform, or the Jefferies analyst report that reduce the price target to $25. I suspect that those actions are related to recent NMS news. <br /><br />NMS accounts for 12.4% of SBRA's annualized revenue as of 12/31/16: <br /><br />Page 9: <br />https://www.sec.gov/Archives/edgar/data/1492298/000149229817000006/sbra10k2016.htm<br /><br />Genesis Healthcare accounted for 32.3% of annualized revenues but SBRA has been selling those facilities. <br /><br /> http://www.sabrahealth.com/GenPage.aspx?IID=4259507&GKP=206527<br /><br />I will vote against the merger. TENNINDEPENDENThttps://www.blogger.com/profile/17444227958539559639noreply@blogger.comtag:blogger.com,1999:blog-2986124651030959736.post-79048717678524625422017-07-09T19:45:53.084-05:002017-07-09T19:45:53.084-05:00Possibly the start of Trump's collusion with t...Possibly the start of Trump's collusion with the Russians??<br /><br />"Donald Trump Jr. met with Russian lawyer promised information helpful to the campaign"<br /><br />http://www.cbsnews.com/news/report-donald-trump-jr-met-with-russian-lawyer-after-promise-of-clinton-information/<br /><br />The truth may never see the light of day. <br /><br />+++<br /><br />An analyst interviewed in a Barron's article predicts that crude oil could rebound to $60 later this year due to demand outpacing supply. <br /><br /> http://www.barrons.com/articles/oil-prices-could-rise-by-35-later-this-year-1499490955<br /><br />I may add to the ETF FENY, which I can buy commission free as a Fidelity customer. My initial position was a 50 share bought at $17.85 bought a few days ago. <br /><br />FIDELITY MSCI ENERGY INDEX<br />https://screener.fidelity.com/ftgw/etf/snapshot/snapshot.jhtml?symbols=FENY<br /> <br /><br />++++++<br /><br />I have nibbled on two Fidelity "factor" ETFs that can be bought commission free at Fidelity. <br /><br />Barron's has an article about factor ETFs in this week's edition (subscription required): <br /><br /> http://www.barrons.com/articles/multifactor-etfs-too-much-of-a-good-thing-1499491795<br /><br />One broad factor ETF is the iShares Edge MSCI Multifactor USA ETF (LRGF): <br /><br />The expense ratio is .2%. <br />https://www.ishares.com/us/products/272824/<br /><br />The Fidelity factor ETFs have a slightly higher expense ratios at .29%.<br /><br />I bought just a few shares of the FIDELITY QUALITY FACTOR ETF (FQAL) and the FIDELITY DIVIDEND ETF FOR RISING RATES (FDRR): <br /><br />https://screener.fidelity.com/ftgw/etf/goto/snapshot/snapshot.jhtml?symbols=FQAL<br /><br />https://screener.fidelity.com/ftgw/etf/goto/snapshot/snapshot.jhtml?symbols=FDRRTENNINDEPENDENThttps://www.blogger.com/profile/17444227958539559639noreply@blogger.comtag:blogger.com,1999:blog-2986124651030959736.post-73911059822384356482017-07-08T12:09:17.962-05:002017-07-08T12:09:17.962-05:00Re: nuclear plant vulnerabilities - I highly recom...Re: nuclear plant vulnerabilities - I highly recommend this eye-opening book on cybercrime:<br /><br />https://www.amazon.com/Future-Crimes-Everything-Connected-Vulnerable-ebook/dp/B00N6PCZMC/ref=sr_1_fkmr0_2?ie=UTF8&qid=1499533181&sr=8-2-fkmr0<br /><br />"By the middle of the first chapter you’ll be afraid to turn on your e-reader or laptop, and you’ll be looking with deep suspicion at your smartphone...[Goodman's] style is breezy but his approach is relentless, as he leads you from the guts of the Target data breach to the security vulnerabilities in social media...Mr. Goodman argues convincingly that we are addressing exponential growth in risky technologies with thinking that is, at best, incremental." — Pittsburgh Post-Gazette<br /><br />InAvalonhttps://www.blogger.com/profile/11099271792479219061noreply@blogger.com